SAN RAMON, Calif. (Business Wire) -- Nextrials, Inc., a leader in clinical research software and services, experienced phenomenal growth in 2005 through new and expanded installations of its flagship product, Prism(R), product enhancements and the addition of key support staff. Revenues in 2005 represent an almost 60 percent increase over 2004 and stand as an endorsement of the pharmaceutical, biotechnology and medical device industries' growing adoption of Internet-based electronic data capture (EDC) technology.
"In 2005, we added features such as automatic safety alert messaging and real-time thesaurus coding to Prism that helped drive increased sales with existing customers. These features also attracted a growing base of first-time users -- broadening the acceptance of our technology," said James Rogers, co-founder and CEO of Nextrials. "The milestones that marked our success include a significant enterprise-wide deployment for a U.S.-based biopharmaceutical company and Prism's selection as a replacement EDC product for an ongoing, international study directed by a U.K.-based specialty pharmaceutical company."
Rogers also pointed to Prism's usage in larger Phase III clinical trials as a reason for the company's rapid revenue growth.
"With the pharmaceutical industry implementing processes designed to reduce paperwork, there is an increasing need for products such as Nextrials' Prism that can help manage data from complex clinical trials that are often conducted over long periods of time and in multiple locations," noted Chris Connor, Senior Research Analyst, IDC Life Science Insights. "Nextrials has consistently presented a forward-thinking view of technology to the EDC market, and as a result, is beginning to show traction in the pharma and biotech markets that it serves."
About Nextrials, Inc.
Founded by pharmaceutical researchers in 1999, Nextrials Innovates for Life(TM) by offering today's most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism(R), its award-winning Electronic Data Capture (EDC) solution, has been used at over 200 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com or call 925-355-3000.
Nextrials, Inc.
James Rogers, 925-355-3000
jrogers@nextrials.com
or
Sterling Communications
Rachel V. Berry, 253-853-5030
rberry@sterlingpr.com
© Business Wire
Only GlobeinvestorGOLD combines the strength of powerful investing tools with the insight of The Globe and Mail.
Discover a wealth of investment information and and exclusive features.
